Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

Patients with recurrent glioblastoma achieving response to bevacizumab combined with chemotherapy have clinical improvement and prolonged survival. High gene expression of angiotensinogen (AGT) is associated with a poor bevacizumab response. Because AGT expression is epigenetically regulated, we aim...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Oncol
Main Authors: Urup, Thomas, Gillberg, Linn, Kaastrup, Katja, Lü, Maya Jeje Schuang, Michaelsen, Signe Regner, Andrée Larsen, Vibeke, Christensen, Ib Jarle, Broholm, Helle, Lassen, Ulrik, Grønbæk, Kirsten, Poulsen, Hans Skovgaard
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7191184/
https://ncbi.nlm.nih.gov/pubmed/32133779
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12660
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados